No limits: NewLimit lands $435m ahead of human trials

The longevity biotech is accelerating toward the clinic after uncovering a promising age-reprogramming therapy years sooner than expected. Every biotech startup promises to push boundaries. Few name themselves after the idea. This week, longevity biotech NewLimit appears to be making a serious attempt to live up to its own branding. The company has raised $435 […] The post No limits: NewLimit lands $435m ahead of human trials appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.